This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.
Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series. He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Training AI/ML tools to predict results of otherwise complex and time-consuming calculations is gaining traction in pharmaceutical R&D. To really benefit from AI, the pharmaceutical industry must be more open to data sharing. Research and Development in the Pharmaceutical Industry | Congressional Budget Office [Internet].
While the Ro5 article highlighted molecular size and lipophilicity as pharmaceutical risk factors, the rule itself is actually of limited utility as a drug design tool. The orchids in Blanchisseuse have been particularly good this year and I’ll include some photos of them to break the text up a bit.
Most pharmaceutical compounds tend to have solubilities somewhere between 1 and 500 µM. Over the last 40 years, the pharmaceutical industry has developed a wide range of invitro and invivo assays for assessing the safety of drug candidates. This is not the case for the ESOL aqueous solubility dataset in MoleculeNet.
Bicyclic structures containing five membered rings such as indoles, consisting of a six-membered benzene ring fused to a five-membered pyrrole ring, are also increasingly relevant as growing research fields such as psychedelics make use of these scaffolds, often found in natural products. 2017, 30, 1, 13–37 [link] 2a Drug Metab.
The papers covered here reflect my research interests and biases, and I’ve certainly overlooked areas that others consider vital. To overcome some of these issues, Joeres and coworkers at the Helmholtz Institute for PharmaceuticalResearch Saarland developed Data Splitting Against Information Leakage (DataSAIL).
Now >20% of all commercialised medicines in the pharmaceutical industry contain a fluorine atom [2]. This was surprising given that replacement of a phenyl with a pyrimidine and fluorination of aryl or heteroaryl rings are techniques often used to increase metabolicstability. Benjamin M. Amaya, Rebecca Durandis, David S.
3 Antibodies are primarily used to target extracellular proteins, though researchers have generated antibodies that can reach intracellular targets. Metabolism was another concern in the early development of macrocyclic peptides. Ajay N Jain Ajay is VP of Research for the Optibrium s BioPharmics Division. Springer, 2019.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content